Global Antibiotic Research and Development Partnership

Global Antibiotic Research and Development Partnership
Name	Global Antibiotic Research and Development Partnership
Formation	2016
Headquarters	Geneva
Type	Public–private partnership
Services	Antibiotic research and development

Global Antibiotic Research and Development Partnership is an international product development partnership focused on accelerating research and development of novel antibiotics to address antimicrobial resistance. The organization engages with a network of pharmaceutical companies, academic institutions, philanthropic foundations, and multilateral agencies to advance candidate compounds through clinical phases and to steward access and stewardship policies. It operates at the intersection of policy coalitions and biomedical innovation efforts linked to global health security and infectious disease control.

History

Established in 2016 amid growing concern about antimicrobial resistance, the Partnership was created through dialogues involving stakeholders such as the World Health Organization, European Commission, Wellcome Trust, and the Bill & Melinda Gates Foundation. Early convenings mirrored initiatives like the AMR Review and the Joint Programming Initiative on Antimicrobial Resistance, responding to reports from bodies such as the UK Government’s advisory panels and recommendations from the G20 health ministers. Initial projects drew on prior collaborations with entities including GlaxoSmithKline, Eli Lilly and Company, and academic centers such as Imperial College London and Johns Hopkins University. Over time, the Partnership aligned with mechanisms promoted at forums like the United Nations General Assembly and the World Economic Forum to integrate R&D incentives and procurement strategies championed by groups including CARB-X and the Coalition for Epidemic Preparedness Innovations.

Mission and Objectives

The Partnership’s mission emphasizes development of antibacterial agents against priority pathogens listed by the World Health Organization and targets identified in the Global Action Plan on Antimicrobial Resistance. Objectives include advancing preclinical candidates to phase 1–3 trials, ensuring equitable access akin to frameworks used by the Global Fund and Gavi, the Vaccine Alliance, and influencing policy instruments similar to those negotiated by the Organisation for Economic Co-operation and Development and the World Trade Organization. It also seeks to coordinate with regulatory agencies such as the European Medicines Agency and the United States Food and Drug Administration to streamline approval pathways and to adopt stewardship measures recommended by the Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control.

Organizational Structure and Governance

Governance draws from models used by the Bill & Melinda Gates Foundation and the Wellcome Trust with an independent board composed of representatives from academic institutions (for example University of Oxford, University of Cambridge), industry partners (for example Novartis, Pfizer), and multilateral partners (for example World Health Organization, World Bank). Operational units mirror programmatic divisions found at Medicines Patent Pool and PATH, including clinical development, regulatory affairs, and access policy teams. Advisory committees include scientific review panels of experts from institutions like Harvard University, Karolinska Institutet, and Institut Pasteur, and ethics oversight influenced by norms from UNICEF and the Council of Europe.

Research and Development Programs

Programs specifically target priority pathogens on lists published by World Health Organization and incorporate approaches seen at Innovative Medicines Initiative consortia and EU Horizon 2020 projects. Candidate portfolios have included small molecules, biologics, and adjunctive therapies developed in collaboration with partners such as AstraZeneca, Bayer, and academic spinouts from Massachusetts Institute of Technology and ETH Zurich. Clinical trials have been run in coordination with trial networks like ISARIC and ClinicalTrials.gov registries, and utilize laboratory standards from Centers for Disease Control and Prevention reference laboratories and protocols aligned with Good Clinical Practice overseen by institutional review boards at universities such as University of Cape Town.

Partnerships and Funding

Funding sources combine philanthropic grants from organizations like the Wellcome Trust and the Bill & Melinda Gates Foundation, public contributions modeled on mechanisms from the European Commission and the UK Research and Innovation council, and in-kind support from pharmaceutical firms including GlaxoSmithKline and Johnson & Johnson. Strategic alliances include coordination with CARB-X, the Global Antibiotic Research & Development Partnership’s peers in the GARDP ecosystem, technical cooperation with WHO Global AMR Surveillance System partners, and procurement dialogue with buyers such as the Global Fund and national health services exemplified by NHS England and Agence nationale de santé publique.

Impact and Outcomes

Outcomes include progression of multiple antibiotic candidates through preclinical and clinical milestones, influence on policy debates at the World Health Assembly and in reports produced by the Interagency Coordination Group on Antimicrobial Resistance, and contributions to capacity-building in clinical trial sites in regions represented by African Union and Pan American Health Organization. The Partnership’s work has informed stewardship guidance disseminated by World Health Organization working groups and contributed data to surveillance efforts maintained by the European Centre for Disease Prevention and Control and US CDC.

Challenges and Criticism

Critiques echo broader debates exemplified by controversies around pharmaceutical incentives discussed in hearings at the United States Congress and analyses by think tanks such as the Brookings Institution and Chatham House. Challenges include financing sustainable late-stage development, negotiating intellectual property arrangements like those addressed by the Medicines Patent Pool, balancing commercial partnerships with public-interest goals as debated in forums including the World Economic Forum, and ensuring equitable access in low- and middle-income settings represented by World Bank analyses. Observers have called for clearer metrics, greater transparency similar to reporting norms at the Open Government Partnership, and stronger alignment with national action plans developed under the auspices of WHO.

Category:International medical and health organizations